Recursion Pharmaceuticals (RXRX)
(Delayed Data from NSDQ)
$7.66 USD
+0.42 (5.80%)
Updated Dec 26, 2024 04:00 PM ET
After-Market: $7.64 -0.02 (-0.26%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth D Momentum F VGM
Recursion Pharmaceuticals (RXRX) Price Targets
| Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
|---|---|---|---|
| $9.86 | $12.00 | $6.00 | 36.19% |
Price Target
Based on short-term price targets offered by seven analysts, the average price target for Recursion Pharmaceuticals comes to $9.86. The forecasts range from a low of $6.00 to a high of $12.00. The average price target represents an increase of 36.19% from the last closing price of $7.24.
Analyst Price Targets (7 )
Find the top stocks with the greatest price target potential and Zacks Rank of 1 or 2
Broker Rating
Recursion Pharmaceuticals currently has an average brokerage recommendation (ABR) of 2.63 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by eight brokerage firms. The current ABR compares to an ABR of 2.63 a month ago based on eight recommendations.
Of the eight recommendations deriving the current ABR, one is Strong Buy and one is Buy. Strong Buy and Buy each account for 12.5% of all recommendations. A month ago, Strong Buy made up 12.5%, while Buy represented 12.5%.
Broker Rating Breakdown
Brokerage Recommendations
| Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 |
| Buy | 1 | 1 | 1 | 1 | 1 |
| Hold | 6 | 6 | 6 | 6 | 6 |
| Sell | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 |
| ABR | 2.63 | 2.63 | 2.63 | 2.63 | 2.63 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
| Date | Brokerage Firm | Analyst | Previous | Current |
|---|---|---|---|---|
| 12/11/2024 | Cowen & Co. | Brendan Smith | Hold | Hold |
| 11/20/2024 | Needham & Company | Gil J Blum | Moderate Buy | Moderate Buy |
| 9/3/2024 | Not Identified | Not Identified | Hold | Hold |
| 9/3/2024 | SVB Securities | Mani Foroohar | Hold | Hold |
| 7/11/2024 | KeyBanc Capital Markets | Scott Schoenhaus | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
| Current ABR | 2.63 |
| ABR (Last week) | 2.63 |
| # of Recs in ABR | 8 |
| Average Target Price | $9.86 |
| LT Growth Rate | 5.60% |
| Industry | Medical - Drugs |
| Industry Rank by ABR | 72 of 251 |
| Current Quarter EPS Est: | -0.35 |
RXRX FAQs
Recursion Pharmaceuticals, Inc. (RXRX) currently has an average brokerage recommendation (ABR) of 2.63 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 8 brokerage firms.
The average price target for Recursion Pharmaceuticals, Inc. (RXRX) is $9.86. The current on short-term price targets is based on 3 reports.
The forecasts for Recursion Pharmaceuticals, Inc. (RXRX) range from a low of $6 to a high of $12. The average price target represents a increase of $36.19 from the last closing price of $7.24.
The current UPSIDE for Recursion Pharmaceuticals, Inc. (RXRX) is 36.19%
Based on short-term price targets offered by seven analysts, the average price target for Recursion Pharmaceuticals comes to $9.86. The forecasts range from a low of $6.00 to a high of $12.00. The average price target represents an increase of 36.19% from the last closing price of $7.24.